Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (06990.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

Market Cap

HKD 114.12B

MomentumView details →

1D Return

−1.49%

YTD Return

+24.40%

RSI (14)

41.9

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

Market Cap

HKD 114.12B

RSI (14)

41.9

MomentumView details →

1D Return

−1.49%

YTD Return

+24.40%

ProfitabilityView details →

Gross Margin

71.88%

Net Margin

−18.59%

EBITDA Margin

−17.72%

ROE (TTM)

−8.60%

ROA (TTM)

−6.99%

Asset Turnover

0.36x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

+36.79%

EPS CAGR 3Y

−38.33%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

HKD 0.24

EPS Surprise

612.46%

Beats (12Q)

1/12

Next Q EPS Est

−HKD 1.75

Avg Surprise (4Q)

612.46%

Rev Surprise

−90.05%

Capital & dividendView details →

Debt/Equity

0.02x

Current Ratio

5.13x

Quick Ratio

4.89x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

2.25B

Net Income (TTM)

−418.48M

Op. CF (TTM)

−191.74M

Next earningsMar 29, 2027 →

Latest newsMore news →

Kelun-Biotech reported its first-half 2026 results, with net profit of 388 million yuan, turning from a loss of 145 million yuan a year earlier.18d ago

Kelun-Biotech's new drug application for sac-TMT (TROP2 ADC) for a new indication in first-line treatment of recurrent or metastatic triple-negative breast cancer has been accepted for review by China's NMPA.36d ago

Similar companies

ORIENT BIO Inc.002630.KS Vaxcell-Bio Therapeutics Co., Ltd.323990.KQ Sino Biopharmaceutical Limited01177.HK Macrogen, Inc.038290.KQ iNtRON Biotechnology, Inc.048530.KQ MedPacto, Inc.235980.KQ Find similar companies →

Latest newsMore news →

Kelun-Biotech reported its first-half 2026 results, with net profit of 388 million yuan, turning from a loss of 145 million yuan a year earlier.18d ago Kelun-Biotech's new drug application for sac-TMT (TROP2 ADC) for a new indication in first-line treatment of recurrent or metastatic triple-negative breast cancer has been accepted for review by China's NMPA.36d ago